Cryo-Cell International Inc. (NYSEAMERICAN:CCEL) Short Interest Down 55.5% in August

Cryo-Cell International Inc. (NYSEAMERICAN:CCEL) was the target of a significant decrease in short interest in the month of August. As of August 31st, there was short interest totaling 5,662 shares, a decrease of 55.5% from the August 15th total of 12,737 shares. Based on an average daily trading volume, of 19,110 shares, the short-interest ratio is presently 0.3 days. Currently, 0.1% of the shares of the company are sold short.

Hedge Funds Weigh In On Cryo-Cell International

A hedge fund recently raised its stake in Cryo-Cell International stock. Susquehanna International Group LLP lifted its stake in Cryo-Cell International Inc. (NYSEAMERICAN:CCEL) by 40.4% in the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 14,064 shares of the company’s stock after purchasing an additional 4,046 shares during the period. Susquehanna International Group LLP owned approximately 0.17% of Cryo-Cell International worth $45,000 as of its most recent SEC filing. 10.44% of the stock is currently owned by institutional investors and hedge funds.

Cryo-Cell International Stock Down 0.7%

NYSEAMERICAN:CCEL traded down $0.03 during midday trading on Monday, reaching $4.37. The stock had a trading volume of 4,440 shares, compared to its average volume of 16,470. The stock has a market cap of $35.22 million, a P/E ratio of -14.57 and a beta of 0.47. The firm has a fifty day simple moving average of $3.79 and a two-hundred day simple moving average of $3.58. Cryo-Cell International has a 12-month low of $2.72 and a 12-month high of $5.01.

Cryo-Cell International (NYSEAMERICAN:CCEL) last posted its quarterly earnings results on Wednesday, July 15th. The company reported $0.07 EPS for the quarter. The business had revenue of $7.78 million during the quarter.

Cryo-Cell International Company Profile

Cryo-Cell International, Inc is a pioneering provider of umbilical cord blood and tissue preservation services. Headquartered in Oldsmar, Florida, the company was founded in 1989 as the first private cord blood bank in the United States. Cryo-Cell operates FDA-registered and AABB-accredited laboratory facilities, maintaining stringent quality control measures and cryogenic storage systems to safeguard stem cell viability over long-term storage periods.

The company’s primary business activity centers on the collection, processing and secure storage of newborn stem cell sources harvested at birth.